Form 4 for NVCR NovoCure Ltd
Accepted 2025-11-04 00:00:00 ET · period of report 2025-11-01 · accession 0001822879-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-04 | 2025-11-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | F - Tax | $12.81 | -966 | 347.7K | -0.3% | -$12.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-11-01 | F | D | 966 | $12.81 | 347,745 | D | — | — | (F1) Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). |